Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin’s Lymphoma
Condition(s):Hodgkin’s LymphomaLast Updated:May 11, 2021Completed
Hide Studies Not Open or Pending
Condition(s):Hodgkin’s LymphomaLast Updated:May 11, 2021Completed
Condition(s):Hodgkin’s LymphomaLast Updated:January 27, 2022Terminated
Condition(s):Chronic Lymphocytic LeukemiaLast Updated:January 27, 2022Terminated
Condition(s):Myeloproliferative DiseasesLast Updated:December 3, 2019Completed
Condition(s):Multiple MyelomaLast Updated:February 2, 2022Terminated
Condition(s):Active Systemic; Onset Juvenile Idiopathic ArthritisLast Updated:May 4, 2021Completed
Condition(s):Polycythemia VeraLast Updated:October 31, 2019Completed
Condition(s):Chronic Myeloproliferative NeoplasmsLast Updated:June 15, 2021Active, not recruiting
Condition(s):Crohn’s DiseaseLast Updated:July 19, 2023Terminated
Condition(s):Autoinflammatory Syndromes; HIDS; TRAPS; Schnitzler’s SyndromeLast Updated:March 1, 2007Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.